The clinical relevance of targeting CSC-associated genes is supported by several recent studies, including CD44 targeting for treatment of acute myeloid leukemia [15], CD24 targeting for treatment of colon and pancreatic cancer [16], and CD133 targeting for hepatocellular and gastric cancer [17]. This evidence concerns the gene CD44 and pancreatic neoplasm.